Study: NCT03792347

Adverse event: Leukopenia
Serious: yes
Organ System: Blood and lymphatic system disorders
Notes: Grade 3 and higher-grade adverse events based on CTCAE 4.0.
Frequency: 2 affected / 20 at risk

Adverse event: Decreased neutrophil count
Serious: yes
Organ System: Blood and lymphatic system disorders
Notes: Grade 3 and higher-grade adverse events based on CTCAE 4.0.
Frequency: 1 affected / 20 at risk

Adverse event: Lymphopenia
Serious: yes
Organ System: Blood and lymphatic system disorders
Notes: Grade 3 and higher-grade adverse events based on CTCAE 4.0.
Frequency: 12 affected / 20 at risk

Adverse event: Oesophageal haemorrhage
Serious: yes
Organ System: Gastrointestinal disorders
Notes: Grade 3 and higher-grade adverse events based on CTCAE 4.0.
Frequency: 1 affected / 20 at risk

Adverse event: Leukopenia
Serious: no
Organ System: Blood and lymphatic system disorders
Notes: Adverse events during neoadjuvant therapy.
Frequency: 18 affected / 20 at risk

Adverse event: Decreased neutrophil count
Serious: no
Organ System: Blood and lymphatic system disorders
Notes: Adverse events during neoadjuvant therapy.
Frequency: 8 affected / 20 at risk

Adverse event: Lymphopenia
Serious: no
Organ System: Blood and lymphatic system disorders
Notes: Adverse events during neoadjuvant therapy.
Frequency: 8 affected / 20 at risk

Adverse event: Anaemia
Serious: no
Organ System: Blood and lymphatic system disorders
Notes: Adverse events during neoadjuvant therapy.
Frequency: 16 affected / 20 at risk

Adverse event: Pneumonitis
Serious: no
Organ System: Respiratory, thoracic and mediastinal disorders
Notes: Adverse events during neoadjuvant therapy.
Frequency: 4 affected / 20 at risk

Adverse event: Alopecia
Serious: no
Organ System: General disorders
Notes: Adverse events during neoadjuvant therapy.
Frequency: 11 affected / 20 at risk

Adverse event: Decreased appetite
Serious: no
Organ System: General disorders
Notes: Adverse events during neoadjuvant therapy.
Frequency: 9 affected / 20 at risk

Adverse event: Constipation
Serious: no
Organ System: Gastrointestinal disorders
Notes: Adverse events during neoadjuvant therapy.
Frequency: 4 affected / 20 at risk

Adverse event: Diarrhoea
Serious: no
Organ System: Gastrointestinal disorders
Notes: Adverse events during neoadjuvant therapy.
Frequency: 2 affected / 20 at risk

Adverse event: Fatigue
Serious: no
Organ System: General disorders
Notes: Adverse events during neoadjuvant therapy.
Frequency: 11 affected / 20 at risk

Adverse event: Nausea
Serious: no
Organ System: Gastrointestinal disorders
Notes: Adverse events during neoadjuvant therapy.
Frequency: 8 affected / 20 at risk

Adverse event: Vomiting
Serious: no
Organ System: Gastrointestinal disorders
Notes: Adverse events during neoadjuvant therapy.
Frequency: 3 affected / 20 at risk

Adverse event: Oesophagitis
Serious: no
Organ System: Gastrointestinal disorders
Notes: Adverse events during neoadjuvant therapy.
Frequency: 11 affected / 20 at risk

Adverse event: Postoperative Pneumonia
Serious: no
Organ System: Respiratory, thoracic and mediastinal disorders
Notes: Postoperative adverse events, which were assessed for 18 participants who underwent surgery.
Frequency: 4 affected / 18 at risk

Adverse event: Atelectasis
Serious: no
Organ System: Respiratory, thoracic and mediastinal disorders
Notes: Postoperative adverse events, which were assessed for 18 participants who underwent surgery.
Frequency: 4 affected / 18 at risk

Adverse event: Pleural effusion
Serious: no
Organ System: Respiratory, thoracic and mediastinal disorders
Notes: Postoperative adverse events, which were assessed for 18 participants who underwent surgery.
Frequency: 3 affected / 18 at risk

Adverse event: Pneumothorax
Serious: no
Organ System: Respiratory, thoracic and mediastinal disorders
Notes: Postoperative adverse events, which were assessed for 18 participants who underwent surgery.
Frequency: 1 affected / 18 at risk

Adverse event: Anastomotic leakage
Serious: no
Organ System: Respiratory, thoracic and mediastinal disorders
Notes: Postoperative adverse events, which were assessed for 18 participants who underwent surgery.
Frequency: 1 affected / 18 at risk

Adverse event: Gastrointestinal fistula
Serious: no
Organ System: Gastrointestinal disorders
Notes: Postoperative adverse events, which were assessed for 18 participants who underwent surgery.
Frequency: 1 affected / 18 at risk

Adverse event: Wound infection
Serious: no
Organ System: Skin and subcutaneous tissue disorders
Notes: Postoperative adverse events, which were assessed for 18 participants who underwent surgery.
Frequency: 1 affected / 18 at risk

Adverse event: Dysphonia
Serious: no
Organ System: Injury, poisoning and procedural complications
Notes: Postoperative adverse events, which were assessed for 18 participants who underwent surgery.
Frequency: 4 affected / 18 at risk

Adverse event: Dysphagia
Serious: no
Organ System: Gastrointestinal disorders
Notes: Postoperative adverse events, which were assessed for 18 participants who underwent surgery.
Frequency: 1 affected / 18 at risk

Adverse event: Postoperative intrathoracic hemorrhage
Serious: no
Organ System: Respiratory, thoracic and mediastinal disorders
Notes: Postoperative adverse events, which were assessed for 18 participants who underwent surgery.
Frequency: 1 affected / 18 at risk